| Income Statement | 2025-09-30 | 2025-06-30 | 2024-09-30 | |
|---|---|---|---|---|
| Research and development | 38,347 | 32,275 | 26,159 | |
| General and administrative | 7,220 | 9,070 | 11,043 | |
| Total operating expenses | 45,567 | 41,345 | 37,202 | |
| Loss from operations | -45,567 | -41,345 | -37,202 | |
| Interest income and other, net | 3,714 | 4,391 | 6,277 | |
| Loss before income taxes | -41,853 | -36,954 | -30,925 | |
| Income tax expense | 196 | 207 | 226 | |
| Net loss | -42,049 | -37,161 | -31,151 | |
| Unrealized gain on available-for-sale investments | 201 | -81 | 921 | |
| Comprehensive loss | -41,848 | -37,242 | -30,230 | |
| Net loss per share - basic | -0.53 | -0.44 | -0.37 | |
| Net loss per share - diluted | -0.53 | -0.44 | -0.37 | |
| Weighted-average number of common shares - basic | 79,052,154 | 83,747,335 | 84,422,000 | |
| Weighted-average number of common shares - diluted | 79,052,154 | 83,747,335 | 84,422,000 | |
Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc. (AVIR)